Know More About Procedure & Surgery

Induction Chemotherapy in Blood Cancer Patients and AML

Induction chemotherapy is a cornerstone in the treatment of aggressive blood cancers, including acute myeloid leukemia (AML). This life-saving approach is the first step in an intensive treatment plan designed to bring the disease into remission. In this blog, we will explore the role of induction chemotherapy in blood cancer patients, with a focus on AML, its purpose, side effects, patient selection, associated risks, and frequently asked questions.

What is Induction Chemotherapy in Blood Cancer?

Induction chemotherapy is the initial phase of chemotherapy treatment aimed at eradicating the bulk of cancer cells in the body. In the context of acute myeloid leukemia (AML), a type of blood cancer that originates in the bone marrow, this treatment is essential for rapidly reducing leukemia cells and restoring healthy blood production.

AML is an aggressive form of leukemia, and without prompt and intensive treatment like induction chemotherapy, the disease can progress quickly, leading to life-threatening complications.

Purpose of Induction Chemotherapy in AML

Induction chemotherapy is the first and most critical step in AML treatment, as it aims to achieve complete remission (CR). Here's a closer look at its objectives:

Eradication of Leukemia Cells

The primary purpose of induction chemotherapy is to destroy as many leukemia cells as possible. AML causes an overproduction of abnormal white blood cells, which crowd out healthy blood cells, leading to anemia, infections, and bleeding problems. Induction chemotherapy reduces these abnormal cells to undetectable levels in the bone marrow and blood.

Achieving Complete Remission

Complete remission (CR) occurs when there is no evidence of leukemia cells in the blood or bone marrow, and normal blood cell production resumes. Induction chemotherapy is designed to bring AML patients into remission quickly, which is the first major goal of treatment.

Preparing for Consolidation Therapy

Once remission is achieved, patients usually require further treatment, known as consolidation therapy, to eliminate any remaining leukemia cells and prevent relapse. Induction chemotherapy sets the stage for this second phase of treatment by reducing the cancer burden.

Side Effects of Induction Chemotherapy in AML

Like all chemotherapy treatments, induction chemotherapy comes with side effects, which can be more pronounced in AML patients due to the aggressive nature of the disease and the intensity of treatment.

Immediate Side Effects

• Nausea and Vomiting: One of the most common side effects of chemotherapy. Anti-nausea medications can help manage these symptoms.
• Fatigue: AML patients often experience extreme tiredness during induction chemotherapy due to the body’s response to both the cancer and the treatment.
• Hair Loss: As with many chemotherapy regimens, patients may lose their hair due to the drugs attacking rapidly dividing cells, including those in hair follicles.

Bone Marrow Suppression

Induction chemotherapy targets the bone marrow, which is responsible for producing blood cells. This leads to bone marrow suppression, which can cause:

• Low red blood cell counts (anemia), leading to fatigue and weakness.
• Low white blood cell counts (neutropenia), increasing the risk of infections.
• Low platelet counts (thrombocytopenia), leading to easy bruising and bleeding.

Infections and Fever

Since chemotherapy weakens the immune system, patients are at high risk for infections. Fever during induction chemotherapy is often an indication of infection, and immediate medical attention is required.

Who Needs Induction Chemotherapy for AML?

Not every leukemia patient will receive induction chemotherapy. The decision to proceed with this treatment depends on several factors related to the type and stage of the cancer, as well as the patient's overall health.

Types of Patients Recommended for Induction Chemotherapy

• Newly Diagnosed AML Patients: Induction chemotherapy is the standard of care for most patients newly diagnosed with AML, especially those with a high percentage of blast cells (immature white blood cells) in their blood or bone marrow.
• Younger Patients: AML patients under 60 are more likely to tolerate the intensive nature of induction chemotherapy and are typically recommended for this treatment.
• Fit Older Patients: Some older patients who are fit and have good organ function may also be candidates for induction chemotherapy.

Who Might Not Be Suitable?

Patients with severe organ dysfunction, multiple co-existing health conditions, or those who are too frail may not be suitable for intensive induction chemotherapy. In these cases, doctors might opt for less aggressive treatments or supportive care to manage symptoms.

Risks of Induction Chemotherapy for AML

While induction chemotherapy is highly effective, it does come with significant risks, particularly for AML patients who may already have compromised immune systems and other health issues.

Increased Risk of Infection

The biggest risk during induction chemotherapy for AML patients is infection. Due to the severe suppression of the immune system, even a minor infection can become life-threatening. Patients are often closely monitored and may require hospitalization to manage infections.

Organ Toxicity

Some chemotherapy drugs used in AML treatment can cause damage to the heart, kidneys, liver, or lungs. This risk increases with age and pre-existing medical conditions, making careful monitoring essential during treatment.

Long-term Risks

• Secondary Cancers: In rare cases, chemotherapy can lead to secondary cancers later in life due to the damage it causes to DNA in healthy cells.
• Fertility Issues: For younger patients, induction chemotherapy may affect fertility, which is an important consideration, especially for those planning to have children in the future.

Frequently Asked Questions (FAQs)

Q. How effective is induction chemotherapy for AML?

A: Induction chemotherapy can be highly effective, leading to remission in up to 70-80% of younger AML patients. However, the success rate varies depending on age, overall health, and specific genetic factors related to the leukemia.

Q. What happens if remission is not achieved after induction chemotherapy?

A: If complete remission is not achieved after the first round of induction chemotherapy, doctors may recommend a second round or alternative treatments such as targeted therapy or participation in clinical trials.

Q. How long does induction chemotherapy last for AML patients?

A: A typical course of induction chemotherapy for AML lasts about 7 days, with 3 days of intensive chemotherapy followed by 4 days of less intense treatment. After this, patients require time for their bone marrow to recover, which can take several weeks.

Q. Can induction chemotherapy cure AML?

A: While induction chemotherapy can achieve remission, it is rarely considered a cure on its own. AML patients often require further treatment, such as consolidation therapy or a stem cell transplant, to ensure long-term remission and minimize the risk of relapse.

Induction chemotherapy is a powerful weapon against acute myeloid leukemia and plays a pivotal role in bringing patients into remission. However, it comes with challenges, including significant side effects and risks that require careful management. Understanding these factors can help patients and their families make informed decisions and prepare for the journey ahead.

------------------------------------------------------------------------------------------------------------------------------------

Connect with us for professional support and answers regarding AML treatment options and patient care.

Call/WhatsApp :+91-8882424372,+91-9910655125 | write us at : query@satyughealthcare.com